olvimulogene nanivacirepvec + platinum chemotherapy + non-platinum chemotherapy + bevacizumab

This combination regimen consists of four components: - **olvimulogene nanivacirepvec**: an oncolytic virus therapy being developed for cancer treatment, designed to infect and lyse tumor cells and stimulate anti-tumor immunity. - **platinum chemotherapy**: refers to platinum-based antineoplastic agents such as cisplatin, carboplatin, or oxaliplatin, which function primarily by crosslinking DNA and inducing cell death in a broad range of cancer types[1][5][7]. - **non-platinum chemotherapy**: refers to classes of cytotoxic anticancer agents not containing platinum, such as taxanes, antimetabolites, topoisomerase inhibitors, etc. These agents disrupt cellular division or DNA synthesis through mechanisms specific to their class. - **bevacizumab**: a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), preventing angiogenesis and thereby inhibiting tumor growth and metastasis[2][6]. This four-drug combination is experimental and primarily investigated for treating solid tumors, often in advanced or metastatic settings. The addition of olvimulogene nanivacirepvec aims to activate the immune system against residual cancer cells while chemotherapies work by direct cytotoxic effects; bevacizumab is included to inhibit formation of new blood vessels required for tumor sustenance[1][2][5][6].